Skip to main content
. 2023 Mar 8;22(6):e13807. doi: 10.1111/acel.13807

FIGURE 8.

FIGURE 8

Apoptosis and protein level in sh‐SLC2A1 experiment and SLC2A1 downregulation improve CAT treatment with OA progression. (a) flow cytometry in sh‐SLC2A1 experiment. (b) Apoptosis in sh‐SLC2A1 experiment. (c) Western blot in sh‐SLC2A1 experiment. (d) Relative protein expression in sh‐SLC2A1 experiment. (e) Three‐dimensional models of mice knee joints were injected intra‐articularly with AAV carrying SLC2A1‐specific shRNA and analyzed 8 weeks after surgery. (f) OARSI score. (g) Osteophyte maturity. (h) Osteophyte size. (i) BV/TV in tibia. (j) Tb.Sp in tibia. (k) BS/TV in tibia. (l) Tb.Th in tibia. (m) Tb.N in tibia. All data are from n = 9 independent experiments. OA, osteoarthritis; CAT, Capsiate; AUC, Area Under The Curve; GSH, glutathione; GSH/GSSH, glutathione/oxidized glutathione; DXA, dual‐energy x‐ray absorptiometry; BV/TV, bone volume over total volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular spacing; OARSI, Osteoarthritis Research Society International. MMP‐13, matrix metalloproteinase‐13; DMM, destabilized medial meniscus;**p < 0.01; ***p < 0.001.